SHINE · Self-Healthcare for breast cancer detection using an INtegrated paper-based Electrochemical device
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-01-07 → 2021-01-06
- EU contribution
- €158,122
- Participants
- 1
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Self-Healthcare for breast cancer detection using an INtegrated paper-based Electrochemical device
Among women, breast cancer is the largest killer in the world. Detecting breast cancer at a curable stage will improve the chance of survival. Although mammography and alternative techniques can diagnose breast cancer, these tests require specialized laboratories and skilled personnel, and suffer of many drawbacks ranging from limitation of mammography to over 40 to the extremely invasive (painful) tissue biopsies. Moreover, tremendous limitations are encountered in low-resource countries, where the maldistribution of cancer care centers, the scarcity of specialists and financial restrictions don't allow all the women to easily access breast cancer screening tests. The presence of circulating mutations opens to a cutting-edge opportunity in cancer diagnosis. Detection of mutations in blood, known as liquid biopsy, offers a revolutionary non-invasive procedure for cancer detection and therapies monitoring. The objective of this project is the development of a hand-held electrochemical microfluidic paper-based analytical device that will enable the rapid detection of breast cancer by the quantitative detection of circulating tumour DNA in whole blood (SHINE).The relevance of this proposal will be in the development of a sensitive, rapid, and cost-effective device that will be used in the personalized medicine by nonspecialists, going beyond the state of the art represented by methods that require skilled personnel, expensive equipment and complicate/time consuming work flow. SHINE will be the first point-of-care device for breast cancer detection that is not currently available. It will be available all over the world and in particular will be used in the developing countries that cannot afford costs of the current breast cancer screening. In addition, SHINE will be a starting point extensible to others cancer liquid biopsies, i.e. pancreatic cancer that is very difficult to detect at a curable stage so far.
Data: CORDIS, © European Union
Project objective
By only considering the United States of America and Europe, 1 in 12 women is affected by Breast cancer (BC). It is the largest killer in the world among women. The only way to fight BC and overcome it, is by diagnosis at curable stage. Although mammography and alternative techniques can diagnose BC, these tests require specialised laboratories and skilled personnel, and suffer of many drawbacks ranging from limitation of mammography to over 40 to the extremely invasive (painful) tissue biopsies. Moreover, tremendous limitations are encountered in low-resource countries, where the maldistribution of cancer care centers, the scarcity of specialists and financial restrictions don't allow all the women to easily access BC screening tests. The presence of circulating mutations, both DNA and RNA, opens to a cutting-edge opportunity in cancer diagnosis. Detection of mutations in blood, known as liquid biopsy, offers a revolutionary non-invasive procedure for cancer diagnosis. Liquid biopsy has been listed on top of the 10 emerging technologies of 2017, and I intend to develop a novel electrochemical platform that can measure mutations in patient blood with unrivalled accuracy. I will develop a screen-printed electrochemical device capable to read out only the mutated DNA sequences associated with BC. Merging different disciplines (molecular biology, nanomaterials, DNA nanotechnology, printed electronics) SHINE will represent the first BC biopsy-free miniaturised tool allowing BC patients to make a quick clinical decision. Importantly, the development of this miniaturised printed diagnostic platform will allow a sensitive, user-friendly, rapid, equipment-free and low-cost device easily deliverable to those areas where laboratory services and resources are limited.
Original text from CORDIS.
Participants
- FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA · BELLATERRA (BARCELONA)CoordinatorSpain
Links
Data: CORDIS, © European Union